Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond

• Published in: Frontiers in oncology Vol. 11; p. 612354
• Main Authors: Orth, Michael, Albrecht, Valerie, Seidl, Karin, Kinzel, Linda, Unger, Kristian, Hess, Julia, Kreutzer, Lisa, Sun, Na, Stegen, Benjamin, Nieto, Alexander, Maas, Jessica, Winssinger, Nicolas, Friedl, Anna A, Walch, Axel K, Belka, Claus, Zitzelsberger, Horst, Niyazi, Maximilian, Lauber, Kirsten
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 17.03.2021
• Subjects: glioblastoma; HSP90 inhibition; HSP90i; NW457; Oncology; radiosensitization; radiotherapy; glioblastoma; HSP90 inhibition; hypermigration; radiosensitization; radiotherapy; HSP90i; NW457
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.612354

Radiotherapy is an essential component of multi-modality treatment of glioblastoma (GBM). However, treatment failure and recurrence are frequent and give rise to the dismal prognosis of this aggressive type of primary brain tumor. A high level of inherent treatment resistance is considered to be the major underlying reason, stemming from constantly activated DNA damage response (DDR) mechanisms as a consequence of oncogene overexpression, persistent replicative stress, and other so far unknown reasons. The molecular chaperone heat shock protein 90 (HSP90) plays an important role in the establishment and maintenance of treatment resistance, since it crucially assists the folding and stabilization of various DDR regulators. Accordingly, inhibition of HSP90 represents a multi-target strategy to interfere with DDR function and to sensitize cancer cells to radiotherapy. Using NW457, a pochoxime-based HSP90 inhibitor with favorable brain pharmacokinetic profile, we show here that HSP90 inhibition at low concentrations with limited cytotoxicity leads to downregulation of various DNA damage response factors on the protein level, distinct transcriptomic alterations, impaired DNA damage repair, and reduced clonogenic survival in response to ionizing irradiation in glioblastoma cells . , HSP90 inhibition by NW457 improved the therapeutic outcome of fractionated CBCT-based irradiation in an orthotopic, syngeneic GBM mouse model, both in terms of tumor progression and survival. Nevertheless, in view of the promising results the efficacy was not as strong as expected, although apart from the radiosensitizing effects HSP90 inhibition also reduced irradiation-induced GBM cell migration and tumor invasiveness. Hence, our findings identify the combination of HSP90 inhibition and radiotherapy in principle as a promising strategy for GBM treatment whose performance needs to be further optimized by improved inhibitor substances, better formulations and/or administration routes, and fine-tuned treatment sequences.